163 related articles for article (PubMed ID: 29714534)
1. Statistical Signal Process in R Language in the Pharmacovigilance Programme of India.
Kumar A; Ahuja J; Shrivastava TP; Kumar V; Kalaiselvan V
Ther Innov Regul Sci; 2018 May; 52(3):329-333. PubMed ID: 29714534
[TBL] [Abstract][Full Text] [Related]
2. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
Singh P; Vaishnav Y; Verma S
Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
[TBL] [Abstract][Full Text] [Related]
3. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in India: Present Scenario and Future Challenges.
Kalaiselvan V; Srivastava S; Singh A; Gupta SK
Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
6. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
Kumar V; Kalaiselvan V; Kumar AP; Saurabh A; Thota P; Sidhu S; Medhi B
Indian J Pharmacol; 2018; 50(4):204-207. PubMed ID: 30505057
[TBL] [Abstract][Full Text] [Related]
7. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance Programme of India: Recent developments and future perspectives.
Kalaiselvan V; Thota P; Singh GN
Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
[TBL] [Abstract][Full Text] [Related]
9. "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India.
Prakash J; Joshi K; Malik D; Mishra O; Sachan A; Kumar B; Bhushan S; Kalaiselvan V; Singh GN
Indian J Pharmacol; 2019; 51(4):236-242. PubMed ID: 31571709
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Methods for the Identification of Signals for Individual Case Safety Reports in India.
Vivekanandan K; Tripathi A; Saurabh A; Kumar R; Kumar R; Prasad T; Singh GN
Ther Innov Regul Sci; 2015 Nov; 49(6):898-902. PubMed ID: 30222376
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
12. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
Scholl JH; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
[TBL] [Abstract][Full Text] [Related]
13. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
14. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
Rehan HS; Sah R; Gupta A; Nagar P
Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
Kalaivani M; Singh A; Kalaiselvan V
MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
[TBL] [Abstract][Full Text] [Related]
16. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India.
Thota P; Thota A; Medhi B; Sidhu S; Kumar P; Selvan VK; Singh GN
Perspect Clin Res; 2018; 9(1):51-55. PubMed ID: 29430420
[TBL] [Abstract][Full Text] [Related]
17. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
18. Pediatric pharmacovigilance in an institute of national importance: Journey has just begun.
Sharma PK; Misra AK; Gupta N; Khera D; Gupta A; Khera P
Indian J Pharmacol; 2017; 49(5):390-395. PubMed ID: 29515280
[TBL] [Abstract][Full Text] [Related]
19. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
20. Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.
Kalaiselvan V; Shukla S; Arora S; Shrivastava TP; Raghuvanshi RS
Front Public Health; 2022; 10():930696. PubMed ID: 36062131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
